nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—lung cancer	0.579	1	CbGaD
Pimecrolimus—CYP3A4—Topotecan—lung cancer	0.0198	0.142	CbGbCtD
Pimecrolimus—CYP3A4—Gefitinib—lung cancer	0.0181	0.13	CbGbCtD
Pimecrolimus—CYP3A4—Teniposide—lung cancer	0.0176	0.126	CbGbCtD
Pimecrolimus—CYP3A4—Vinorelbine—lung cancer	0.014	0.1	CbGbCtD
Pimecrolimus—CYP3A4—Crizotinib—lung cancer	0.0111	0.0796	CbGbCtD
Pimecrolimus—CYP3A4—Erlotinib—lung cancer	0.0107	0.0768	CbGbCtD
Pimecrolimus—CYP3A4—Paclitaxel—lung cancer	0.00982	0.0703	CbGbCtD
Pimecrolimus—CYP3A4—Irinotecan—lung cancer	0.00969	0.0694	CbGbCtD
Pimecrolimus—CYP3A4—Vinblastine—lung cancer	0.00861	0.0617	CbGbCtD
Pimecrolimus—CYP3A4—Etoposide—lung cancer	0.00776	0.0556	CbGbCtD
Pimecrolimus—CYP3A4—Docetaxel—lung cancer	0.0071	0.0508	CbGbCtD
Pimecrolimus—CYP3A4—Doxorubicin—lung cancer	0.00529	0.0379	CbGbCtD
Pimecrolimus—MTOR—mammary gland—lung cancer	0.00335	0.134	CbGeAlD
Pimecrolimus—FKBP1A—mammary gland—lung cancer	0.00302	0.121	CbGeAlD
Pimecrolimus—MTOR—respiratory system—lung cancer	0.00224	0.0895	CbGeAlD
Pimecrolimus—FKBP1A—respiratory system—lung cancer	0.00201	0.0805	CbGeAlD
Pimecrolimus—MTOR—epithelium—lung cancer	0.00187	0.0748	CbGeAlD
Pimecrolimus—FKBP1A—epithelium—lung cancer	0.00168	0.0672	CbGeAlD
Pimecrolimus—Everolimus—MTOR—lung cancer	0.00166	0.304	CrCbGaD
Pimecrolimus—FKBP1A—bronchus—lung cancer	0.00165	0.0662	CbGeAlD
Pimecrolimus—FKBP1A—trachea—lung cancer	0.00149	0.0595	CbGeAlD
Pimecrolimus—FKBP1A—cardiac atrium—lung cancer	0.0014	0.0559	CbGeAlD
Pimecrolimus—MTOR—bone marrow—lung cancer	0.00131	0.0524	CbGeAlD
Pimecrolimus—MTOR—lung—lung cancer	0.00119	0.0475	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—lung cancer	0.00118	0.0472	CbGeAlD
Pimecrolimus—Temsirolimus—MTOR—lung cancer	0.00112	0.205	CrCbGaD
Pimecrolimus—FKBP1A—lung—lung cancer	0.00107	0.0427	CbGeAlD
Pimecrolimus—Sirolimus—MTOR—lung cancer	0.000985	0.181	CrCbGaD
Pimecrolimus—Tacrolimus—MTOR—lung cancer	0.000985	0.181	CrCbGaD
Pimecrolimus—MTOR—lymph node—lung cancer	0.000812	0.0325	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—lung cancer	0.00073	0.0292	CbGeAlD
Pimecrolimus—Temsirolimus—ABCB1—lung cancer	0.000192	0.0353	CrCbGaD
Pimecrolimus—Tacrolimus—ALB—lung cancer	0.000177	0.0325	CrCbGaD
Pimecrolimus—Sirolimus—ABCB1—lung cancer	0.000169	0.031	CrCbGaD
Pimecrolimus—Tacrolimus—ABCB1—lung cancer	0.000169	0.031	CrCbGaD
Pimecrolimus—Diarrhoea—Topotecan—lung cancer	0.000123	0.001	CcSEcCtD
Pimecrolimus—Infection—Gemcitabine—lung cancer	0.000123	0.001	CcSEcCtD
Pimecrolimus—Back pain—Paclitaxel—lung cancer	0.000123	0.001	CcSEcCtD
Pimecrolimus—Pharyngitis—Docetaxel—lung cancer	0.000123	0.001	CcSEcCtD
Pimecrolimus—Urticaria—Vinorelbine—lung cancer	0.000122	0.000998	CcSEcCtD
Pimecrolimus—Diarrhoea—Erlotinib—lung cancer	0.000122	0.000994	CcSEcCtD
Pimecrolimus—Abdominal pain—Vinorelbine—lung cancer	0.000122	0.000993	CcSEcCtD
Pimecrolimus—Body temperature increased—Vinorelbine—lung cancer	0.000122	0.000993	CcSEcCtD
Pimecrolimus—Nervous system disorder—Gemcitabine—lung cancer	0.000121	0.00099	CcSEcCtD
Pimecrolimus—Skin disorder—Gemcitabine—lung cancer	0.00012	0.00098	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000119	0.000975	CcSEcCtD
Pimecrolimus—Dermatitis exfoliative—Doxorubicin—lung cancer	0.000118	0.000964	CcSEcCtD
Pimecrolimus—Vomiting—Vinblastine—lung cancer	0.000118	0.000961	CcSEcCtD
Pimecrolimus—Breast disorder—Methotrexate—lung cancer	0.000116	0.000949	CcSEcCtD
Pimecrolimus—Headache—Vinblastine—lung cancer	0.000116	0.000947	CcSEcCtD
Pimecrolimus—Angioedema—Paclitaxel—lung cancer	0.000116	0.000946	CcSEcCtD
Pimecrolimus—Eye disorder—Docetaxel—lung cancer	0.000115	0.000942	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Cisplatin—lung cancer	0.000115	0.000941	CcSEcCtD
Pimecrolimus—Oedema—Cisplatin—lung cancer	0.000115	0.000941	CcSEcCtD
Pimecrolimus—Flushing—Docetaxel—lung cancer	0.000115	0.000936	CcSEcCtD
Pimecrolimus—Infection—Cisplatin—lung cancer	0.000115	0.000935	CcSEcCtD
Pimecrolimus—Vomiting—Topotecan—lung cancer	0.000114	0.000934	CcSEcCtD
Pimecrolimus—Paraesthesia—Irinotecan—lung cancer	0.000114	0.00093	CcSEcCtD
Pimecrolimus—Rash—Topotecan—lung cancer	0.000114	0.000926	CcSEcCtD
Pimecrolimus—Hypersensitivity—Vinorelbine—lung cancer	0.000113	0.000926	CcSEcCtD
Pimecrolimus—Dermatitis—Topotecan—lung cancer	0.000113	0.000925	CcSEcCtD
Pimecrolimus—Vomiting—Erlotinib—lung cancer	0.000113	0.000924	CcSEcCtD
Pimecrolimus—Dyspnoea—Irinotecan—lung cancer	0.000113	0.000924	CcSEcCtD
Pimecrolimus—Nervous system disorder—Cisplatin—lung cancer	0.000113	0.000923	CcSEcCtD
Pimecrolimus—Cough—Etoposide—lung cancer	0.000113	0.000922	CcSEcCtD
Pimecrolimus—Headache—Topotecan—lung cancer	0.000113	0.00092	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000113	0.00092	CcSEcCtD
Pimecrolimus—Rash—Erlotinib—lung cancer	0.000112	0.000916	CcSEcCtD
Pimecrolimus—Dermatitis—Erlotinib—lung cancer	0.000112	0.000915	CcSEcCtD
Pimecrolimus—Skin disorder—Cisplatin—lung cancer	0.000112	0.000914	CcSEcCtD
Pimecrolimus—Immune system disorder—Docetaxel—lung cancer	0.000112	0.000911	CcSEcCtD
Pimecrolimus—Headache—Erlotinib—lung cancer	0.000112	0.00091	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Docetaxel—lung cancer	0.000111	0.000909	CcSEcCtD
Pimecrolimus—Asthma—Methotrexate—lung cancer	0.000111	0.000908	CcSEcCtD
Pimecrolimus—Paraesthesia—Gemcitabine—lung cancer	0.000111	0.000906	CcSEcCtD
Pimecrolimus—Cough—Paclitaxel—lung cancer	0.000111	0.000904	CcSEcCtD
Pimecrolimus—Dyspnoea—Gemcitabine—lung cancer	0.00011	0.0009	CcSEcCtD
Pimecrolimus—Nausea—Vinblastine—lung cancer	0.00011	0.000898	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Irinotecan—lung cancer	0.00011	0.000895	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000109	0.000893	CcSEcCtD
Pimecrolimus—Pruritus—Vinorelbine—lung cancer	0.000109	0.000889	CcSEcCtD
Pimecrolimus—Constipation—Irinotecan—lung cancer	0.000109	0.000886	CcSEcCtD
Pimecrolimus—Pain—Irinotecan—lung cancer	0.000109	0.000886	CcSEcCtD
Pimecrolimus—Arthralgia—Paclitaxel—lung cancer	0.000108	0.000882	CcSEcCtD
Pimecrolimus—Face oedema—Doxorubicin—lung cancer	0.000108	0.000878	CcSEcCtD
Pimecrolimus—Malnutrition—Docetaxel—lung cancer	0.000108	0.000878	CcSEcCtD
Pimecrolimus—Erythema—Docetaxel—lung cancer	0.000108	0.000878	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000107	0.000875	CcSEcCtD
Pimecrolimus—Nausea—Topotecan—lung cancer	0.000107	0.000872	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000107	0.000871	CcSEcCtD
Pimecrolimus—Constipation—Gemcitabine—lung cancer	0.000106	0.000863	CcSEcCtD
Pimecrolimus—Pain—Gemcitabine—lung cancer	0.000106	0.000863	CcSEcCtD
Pimecrolimus—Nausea—Erlotinib—lung cancer	0.000106	0.000863	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Etoposide—lung cancer	0.000106	0.000862	CcSEcCtD
Pimecrolimus—Diarrhoea—Vinorelbine—lung cancer	0.000105	0.00086	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000105	0.000857	CcSEcCtD
Pimecrolimus—Infection—Etoposide—lung cancer	0.000105	0.000856	CcSEcCtD
Pimecrolimus—Back pain—Docetaxel—lung cancer	0.000104	0.000849	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Irinotecan—lung cancer	0.000104	0.000847	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Paclitaxel—lung cancer	0.000104	0.000845	CcSEcCtD
Pimecrolimus—Oedema—Paclitaxel—lung cancer	0.000104	0.000845	CcSEcCtD
Pimecrolimus—Paraesthesia—Cisplatin—lung cancer	0.000104	0.000845	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Methotrexate—lung cancer	0.000103	0.000844	CcSEcCtD
Pimecrolimus—Infection—Paclitaxel—lung cancer	0.000103	0.00084	CcSEcCtD
Pimecrolimus—Dyspnoea—Cisplatin—lung cancer	0.000103	0.000839	CcSEcCtD
Pimecrolimus—Skin disorder—Etoposide—lung cancer	0.000103	0.000837	CcSEcCtD
Pimecrolimus—Abdominal pain upper—Doxorubicin—lung cancer	0.000102	0.000831	CcSEcCtD
Pimecrolimus—Nervous system disorder—Paclitaxel—lung cancer	0.000102	0.000829	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Methotrexate—lung cancer	0.000102	0.000829	CcSEcCtD
Pimecrolimus—Breast disorder—Doxorubicin—lung cancer	0.000101	0.000822	CcSEcCtD
Pimecrolimus—Skin disorder—Paclitaxel—lung cancer	0.000101	0.000821	CcSEcCtD
Pimecrolimus—Abdominal pain—Irinotecan—lung cancer	0.0001	0.000819	CcSEcCtD
Pimecrolimus—Body temperature increased—Irinotecan—lung cancer	0.0001	0.000819	CcSEcCtD
Pimecrolimus—Pneumonia—Methotrexate—lung cancer	9.98e-05	0.000814	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Doxorubicin—lung cancer	9.97e-05	0.000813	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Cisplatin—lung cancer	9.96e-05	0.000812	CcSEcCtD
Pimecrolimus—Infestation NOS—Methotrexate—lung cancer	9.92e-05	0.000809	CcSEcCtD
Pimecrolimus—Infestation—Methotrexate—lung cancer	9.92e-05	0.000809	CcSEcCtD
Pimecrolimus—Pain—Cisplatin—lung cancer	9.86e-05	0.000805	CcSEcCtD
Pimecrolimus—Vomiting—Vinorelbine—lung cancer	9.79e-05	0.000799	CcSEcCtD
Pimecrolimus—Body temperature increased—Gemcitabine—lung cancer	9.78e-05	0.000798	CcSEcCtD
Pimecrolimus—Rash—Vinorelbine—lung cancer	9.71e-05	0.000792	CcSEcCtD
Pimecrolimus—Dermatitis—Vinorelbine—lung cancer	9.7e-05	0.000791	CcSEcCtD
Pimecrolimus—Headache—Vinorelbine—lung cancer	9.65e-05	0.000787	CcSEcCtD
Pimecrolimus—Conjunctivitis—Methotrexate—lung cancer	9.64e-05	0.000787	CcSEcCtD
Pimecrolimus—Asthma—Doxorubicin—lung cancer	9.64e-05	0.000786	CcSEcCtD
Pimecrolimus—Influenza—Doxorubicin—lung cancer	9.64e-05	0.000786	CcSEcCtD
Pimecrolimus—Paraesthesia—Etoposide—lung cancer	9.49e-05	0.000774	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Paclitaxel—lung cancer	9.44e-05	0.00077	CcSEcCtD
Pimecrolimus—Dyspnoea—Etoposide—lung cancer	9.42e-05	0.000768	CcSEcCtD
Pimecrolimus—Cough—Docetaxel—lung cancer	9.39e-05	0.000766	CcSEcCtD
Pimecrolimus—Epistaxis—Methotrexate—lung cancer	9.36e-05	0.000764	CcSEcCtD
Pimecrolimus—Hypersensitivity—Irinotecan—lung cancer	9.36e-05	0.000763	CcSEcCtD
Pimecrolimus—Paraesthesia—Paclitaxel—lung cancer	9.3e-05	0.000759	CcSEcCtD
Pimecrolimus—Bronchitis—Doxorubicin—lung cancer	9.27e-05	0.000756	CcSEcCtD
Pimecrolimus—Dyspnoea—Paclitaxel—lung cancer	9.23e-05	0.000753	CcSEcCtD
Pimecrolimus—Arthralgia—Docetaxel—lung cancer	9.16e-05	0.000747	CcSEcCtD
Pimecrolimus—Nausea—Vinorelbine—lung cancer	9.15e-05	0.000746	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Etoposide—lung cancer	9.12e-05	0.000744	CcSEcCtD
Pimecrolimus—Body temperature increased—Cisplatin—lung cancer	9.12e-05	0.000744	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	9.1e-05	0.000742	CcSEcCtD
Pimecrolimus—Constipation—Etoposide—lung cancer	9.03e-05	0.000737	CcSEcCtD
Pimecrolimus—Pain—Etoposide—lung cancer	9.03e-05	0.000737	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Doxorubicin—lung cancer	8.96e-05	0.000731	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Paclitaxel—lung cancer	8.94e-05	0.00073	CcSEcCtD
Pimecrolimus—Constipation—Paclitaxel—lung cancer	8.86e-05	0.000723	CcSEcCtD
Pimecrolimus—Pain—Paclitaxel—lung cancer	8.86e-05	0.000723	CcSEcCtD
Pimecrolimus—Pharyngitis—Methotrexate—lung cancer	8.84e-05	0.000721	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Doxorubicin—lung cancer	8.8e-05	0.000718	CcSEcCtD
Pimecrolimus—Oedema—Docetaxel—lung cancer	8.78e-05	0.000716	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Docetaxel—lung cancer	8.78e-05	0.000716	CcSEcCtD
Pimecrolimus—Pruritus—Gemcitabine—lung cancer	8.75e-05	0.000714	CcSEcCtD
Pimecrolimus—Infection—Docetaxel—lung cancer	8.72e-05	0.000712	CcSEcCtD
Pimecrolimus—Diarrhoea—Irinotecan—lung cancer	8.69e-05	0.000709	CcSEcCtD
Pimecrolimus—Pneumonia—Doxorubicin—lung cancer	8.64e-05	0.000705	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Etoposide—lung cancer	8.64e-05	0.000705	CcSEcCtD
Pimecrolimus—Nervous system disorder—Docetaxel—lung cancer	8.61e-05	0.000702	CcSEcCtD
Pimecrolimus—Infestation—Doxorubicin—lung cancer	8.59e-05	0.000701	CcSEcCtD
Pimecrolimus—Infestation NOS—Doxorubicin—lung cancer	8.59e-05	0.000701	CcSEcCtD
Pimecrolimus—Skin disorder—Docetaxel—lung cancer	8.53e-05	0.000696	CcSEcCtD
Pimecrolimus—Hypersensitivity—Cisplatin—lung cancer	8.5e-05	0.000693	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Paclitaxel—lung cancer	8.47e-05	0.000691	CcSEcCtD
Pimecrolimus—Diarrhoea—Gemcitabine—lung cancer	8.47e-05	0.000691	CcSEcCtD
Pimecrolimus—Urticaria—Etoposide—lung cancer	8.39e-05	0.000685	CcSEcCtD
Pimecrolimus—Abdominal pain—Etoposide—lung cancer	8.35e-05	0.000681	CcSEcCtD
Pimecrolimus—Body temperature increased—Etoposide—lung cancer	8.35e-05	0.000681	CcSEcCtD
Pimecrolimus—Conjunctivitis—Doxorubicin—lung cancer	8.35e-05	0.000681	CcSEcCtD
Pimecrolimus—Eye disorder—Methotrexate—lung cancer	8.32e-05	0.000679	CcSEcCtD
Pimecrolimus—Urticaria—Paclitaxel—lung cancer	8.23e-05	0.000671	CcSEcCtD
Pimecrolimus—Body temperature increased—Paclitaxel—lung cancer	8.19e-05	0.000668	CcSEcCtD
Pimecrolimus—Abdominal pain—Paclitaxel—lung cancer	8.19e-05	0.000668	CcSEcCtD
Pimecrolimus—Epistaxis—Doxorubicin—lung cancer	8.1e-05	0.000661	CcSEcCtD
Pimecrolimus—Vomiting—Irinotecan—lung cancer	8.08e-05	0.000659	CcSEcCtD
Pimecrolimus—Sinusitis—Doxorubicin—lung cancer	8.06e-05	0.000658	CcSEcCtD
Pimecrolimus—Immune system disorder—Methotrexate—lung cancer	8.05e-05	0.000656	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Methotrexate—lung cancer	8.03e-05	0.000655	CcSEcCtD
Pimecrolimus—Rash—Irinotecan—lung cancer	8.01e-05	0.000653	CcSEcCtD
Pimecrolimus—Dermatitis—Irinotecan—lung cancer	8e-05	0.000653	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Docetaxel—lung cancer	8e-05	0.000653	CcSEcCtD
Pimecrolimus—Headache—Irinotecan—lung cancer	7.96e-05	0.000649	CcSEcCtD
Pimecrolimus—Diarrhoea—Cisplatin—lung cancer	7.89e-05	0.000644	CcSEcCtD
Pimecrolimus—Paraesthesia—Docetaxel—lung cancer	7.88e-05	0.000643	CcSEcCtD
Pimecrolimus—Vomiting—Gemcitabine—lung cancer	7.87e-05	0.000642	CcSEcCtD
Pimecrolimus—Dyspnoea—Docetaxel—lung cancer	7.83e-05	0.000639	CcSEcCtD
Pimecrolimus—Rash—Gemcitabine—lung cancer	7.8e-05	0.000636	CcSEcCtD
Pimecrolimus—Dermatitis—Gemcitabine—lung cancer	7.79e-05	0.000636	CcSEcCtD
Pimecrolimus—Hypersensitivity—Etoposide—lung cancer	7.78e-05	0.000635	CcSEcCtD
Pimecrolimus—Erythema—Methotrexate—lung cancer	7.75e-05	0.000633	CcSEcCtD
Pimecrolimus—Malnutrition—Methotrexate—lung cancer	7.75e-05	0.000633	CcSEcCtD
Pimecrolimus—Headache—Gemcitabine—lung cancer	7.75e-05	0.000632	CcSEcCtD
Pimecrolimus—Rhinitis—Doxorubicin—lung cancer	7.73e-05	0.000631	CcSEcCtD
Pimecrolimus—Pharyngitis—Doxorubicin—lung cancer	7.65e-05	0.000625	CcSEcCtD
Pimecrolimus—Hypersensitivity—Paclitaxel—lung cancer	7.63e-05	0.000623	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Docetaxel—lung cancer	7.58e-05	0.000618	CcSEcCtD
Pimecrolimus—Nausea—Irinotecan—lung cancer	7.54e-05	0.000615	CcSEcCtD
Pimecrolimus—Constipation—Docetaxel—lung cancer	7.51e-05	0.000613	CcSEcCtD
Pimecrolimus—Pain—Docetaxel—lung cancer	7.51e-05	0.000613	CcSEcCtD
Pimecrolimus—Back pain—Methotrexate—lung cancer	7.5e-05	0.000612	CcSEcCtD
Pimecrolimus—Pruritus—Etoposide—lung cancer	7.47e-05	0.00061	CcSEcCtD
Pimecrolimus—Nausea—Gemcitabine—lung cancer	7.35e-05	0.0006	CcSEcCtD
Pimecrolimus—Vomiting—Cisplatin—lung cancer	7.33e-05	0.000598	CcSEcCtD
Pimecrolimus—Pruritus—Paclitaxel—lung cancer	7.33e-05	0.000598	CcSEcCtD
Pimecrolimus—Rash—Cisplatin—lung cancer	7.27e-05	0.000593	CcSEcCtD
Pimecrolimus—Dermatitis—Cisplatin—lung cancer	7.26e-05	0.000593	CcSEcCtD
Pimecrolimus—Diarrhoea—Etoposide—lung cancer	7.23e-05	0.00059	CcSEcCtD
Pimecrolimus—Eye disorder—Doxorubicin—lung cancer	7.21e-05	0.000588	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Docetaxel—lung cancer	7.18e-05	0.000586	CcSEcCtD
Pimecrolimus—Flushing—Doxorubicin—lung cancer	7.16e-05	0.000584	CcSEcCtD
Pimecrolimus—Diarrhoea—Paclitaxel—lung cancer	7.09e-05	0.000578	CcSEcCtD
Pimecrolimus—Immune system disorder—Doxorubicin—lung cancer	6.97e-05	0.000568	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Doxorubicin—lung cancer	6.95e-05	0.000567	CcSEcCtD
Pimecrolimus—Body temperature increased—Docetaxel—lung cancer	6.94e-05	0.000566	CcSEcCtD
Pimecrolimus—Abdominal pain—Docetaxel—lung cancer	6.94e-05	0.000566	CcSEcCtD
Pimecrolimus—Nausea—Cisplatin—lung cancer	6.85e-05	0.000559	CcSEcCtD
Pimecrolimus—Cough—Methotrexate—lung cancer	6.77e-05	0.000552	CcSEcCtD
Pimecrolimus—Vomiting—Etoposide—lung cancer	6.72e-05	0.000548	CcSEcCtD
Pimecrolimus—Erythema—Doxorubicin—lung cancer	6.71e-05	0.000548	CcSEcCtD
Pimecrolimus—Malnutrition—Doxorubicin—lung cancer	6.71e-05	0.000548	CcSEcCtD
Pimecrolimus—Rash—Etoposide—lung cancer	6.66e-05	0.000543	CcSEcCtD
Pimecrolimus—Dermatitis—Etoposide—lung cancer	6.66e-05	0.000543	CcSEcCtD
Pimecrolimus—Headache—Etoposide—lung cancer	6.62e-05	0.00054	CcSEcCtD
Pimecrolimus—Arthralgia—Methotrexate—lung cancer	6.6e-05	0.000539	CcSEcCtD
Pimecrolimus—Vomiting—Paclitaxel—lung cancer	6.59e-05	0.000537	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	6.56e-05	0.000535	CcSEcCtD
Pimecrolimus—Rash—Paclitaxel—lung cancer	6.53e-05	0.000533	CcSEcCtD
Pimecrolimus—Dermatitis—Paclitaxel—lung cancer	6.53e-05	0.000532	CcSEcCtD
Pimecrolimus—Back pain—Doxorubicin—lung cancer	6.49e-05	0.00053	CcSEcCtD
Pimecrolimus—Headache—Paclitaxel—lung cancer	6.49e-05	0.000529	CcSEcCtD
Pimecrolimus—Hypersensitivity—Docetaxel—lung cancer	6.47e-05	0.000528	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Methotrexate—lung cancer	6.33e-05	0.000516	CcSEcCtD
Pimecrolimus—Infection—Methotrexate—lung cancer	6.29e-05	0.000513	CcSEcCtD
Pimecrolimus—Nausea—Etoposide—lung cancer	6.28e-05	0.000512	CcSEcCtD
Pimecrolimus—Pruritus—Docetaxel—lung cancer	6.21e-05	0.000507	CcSEcCtD
Pimecrolimus—Nervous system disorder—Methotrexate—lung cancer	6.21e-05	0.000506	CcSEcCtD
Pimecrolimus—Nausea—Paclitaxel—lung cancer	6.15e-05	0.000502	CcSEcCtD
Pimecrolimus—Skin disorder—Methotrexate—lung cancer	6.15e-05	0.000501	CcSEcCtD
Pimecrolimus—Diarrhoea—Docetaxel—lung cancer	6.01e-05	0.00049	CcSEcCtD
Pimecrolimus—Cough—Doxorubicin—lung cancer	5.86e-05	0.000478	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Methotrexate—lung cancer	5.77e-05	0.00047	CcSEcCtD
Pimecrolimus—Arthralgia—Doxorubicin—lung cancer	5.72e-05	0.000466	CcSEcCtD
Pimecrolimus—Paraesthesia—Methotrexate—lung cancer	5.68e-05	0.000464	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	5.68e-05	0.000463	CcSEcCtD
Pimecrolimus—Dyspnoea—Methotrexate—lung cancer	5.64e-05	0.00046	CcSEcCtD
Pimecrolimus—Vomiting—Docetaxel—lung cancer	5.58e-05	0.000455	CcSEcCtD
Pimecrolimus—Rash—Docetaxel—lung cancer	5.54e-05	0.000452	CcSEcCtD
Pimecrolimus—Dermatitis—Docetaxel—lung cancer	5.53e-05	0.000451	CcSEcCtD
Pimecrolimus—Headache—Docetaxel—lung cancer	5.5e-05	0.000449	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Doxorubicin—lung cancer	5.48e-05	0.000447	CcSEcCtD
Pimecrolimus—Oedema—Doxorubicin—lung cancer	5.48e-05	0.000447	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Methotrexate—lung cancer	5.46e-05	0.000446	CcSEcCtD
Pimecrolimus—Infection—Doxorubicin—lung cancer	5.44e-05	0.000444	CcSEcCtD
Pimecrolimus—Pain—Methotrexate—lung cancer	5.41e-05	0.000441	CcSEcCtD
Pimecrolimus—Nervous system disorder—Doxorubicin—lung cancer	5.37e-05	0.000438	CcSEcCtD
Pimecrolimus—Skin disorder—Doxorubicin—lung cancer	5.32e-05	0.000434	CcSEcCtD
Pimecrolimus—Nausea—Docetaxel—lung cancer	5.22e-05	0.000425	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Methotrexate—lung cancer	5.17e-05	0.000422	CcSEcCtD
Pimecrolimus—Urticaria—Methotrexate—lung cancer	5.03e-05	0.00041	CcSEcCtD
Pimecrolimus—Abdominal pain—Methotrexate—lung cancer	5e-05	0.000408	CcSEcCtD
Pimecrolimus—Body temperature increased—Methotrexate—lung cancer	5e-05	0.000408	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Doxorubicin—lung cancer	4.99e-05	0.000407	CcSEcCtD
Pimecrolimus—Paraesthesia—Doxorubicin—lung cancer	4.92e-05	0.000401	CcSEcCtD
Pimecrolimus—Dyspnoea—Doxorubicin—lung cancer	4.89e-05	0.000399	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Doxorubicin—lung cancer	4.73e-05	0.000386	CcSEcCtD
Pimecrolimus—Constipation—Doxorubicin—lung cancer	4.69e-05	0.000382	CcSEcCtD
Pimecrolimus—Pain—Doxorubicin—lung cancer	4.69e-05	0.000382	CcSEcCtD
Pimecrolimus—Hypersensitivity—Methotrexate—lung cancer	4.66e-05	0.00038	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Doxorubicin—lung cancer	4.48e-05	0.000366	CcSEcCtD
Pimecrolimus—Pruritus—Methotrexate—lung cancer	4.48e-05	0.000365	CcSEcCtD
Pimecrolimus—Urticaria—Doxorubicin—lung cancer	4.35e-05	0.000355	CcSEcCtD
Pimecrolimus—Abdominal pain—Doxorubicin—lung cancer	4.33e-05	0.000353	CcSEcCtD
Pimecrolimus—Body temperature increased—Doxorubicin—lung cancer	4.33e-05	0.000353	CcSEcCtD
Pimecrolimus—Diarrhoea—Methotrexate—lung cancer	4.33e-05	0.000353	CcSEcCtD
Pimecrolimus—Hypersensitivity—Doxorubicin—lung cancer	4.04e-05	0.000329	CcSEcCtD
Pimecrolimus—Vomiting—Methotrexate—lung cancer	4.02e-05	0.000328	CcSEcCtD
Pimecrolimus—Rash—Methotrexate—lung cancer	3.99e-05	0.000326	CcSEcCtD
Pimecrolimus—Dermatitis—Methotrexate—lung cancer	3.99e-05	0.000325	CcSEcCtD
Pimecrolimus—Headache—Methotrexate—lung cancer	3.96e-05	0.000323	CcSEcCtD
Pimecrolimus—Pruritus—Doxorubicin—lung cancer	3.88e-05	0.000316	CcSEcCtD
Pimecrolimus—Nausea—Methotrexate—lung cancer	3.76e-05	0.000307	CcSEcCtD
Pimecrolimus—Diarrhoea—Doxorubicin—lung cancer	3.75e-05	0.000306	CcSEcCtD
Pimecrolimus—Vomiting—Doxorubicin—lung cancer	3.48e-05	0.000284	CcSEcCtD
Pimecrolimus—Rash—Doxorubicin—lung cancer	3.45e-05	0.000282	CcSEcCtD
Pimecrolimus—Dermatitis—Doxorubicin—lung cancer	3.45e-05	0.000282	CcSEcCtD
Pimecrolimus—Headache—Doxorubicin—lung cancer	3.43e-05	0.00028	CcSEcCtD
Pimecrolimus—Nausea—Doxorubicin—lung cancer	3.25e-05	0.000266	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CD4—lung cancer	1.55e-05	0.000121	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HES1—lung cancer	1.54e-05	0.00012	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KDR—lung cancer	1.54e-05	0.00012	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTGS2—lung cancer	1.54e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—lung cancer	1.53e-05	0.00012	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB3—lung cancer	1.53e-05	0.000119	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FLT1—lung cancer	1.5e-05	0.000117	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APP—lung cancer	1.47e-05	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NOTCH3—lung cancer	1.47e-05	0.000114	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGF9—lung cancer	1.46e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—JUN—lung cancer	1.45e-05	0.000113	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERCC2—lung cancer	1.44e-05	0.000112	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—FGFR1—lung cancer	1.42e-05	0.000111	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—lung cancer	1.42e-05	0.00011	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—APC—lung cancer	1.42e-05	0.00011	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CG—lung cancer	1.42e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—lung cancer	1.42e-05	0.00011	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ATP5H—lung cancer	1.41e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB3—lung cancer	1.41e-05	0.00011	CbGpPWpGaD
Pimecrolimus—CYP3A4—Biological oxidations—POMC—lung cancer	1.41e-05	0.00011	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CDKN1A—lung cancer	1.4e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—BCL2L1—lung cancer	1.4e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PTEN—lung cancer	1.4e-05	0.000109	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGF—lung cancer	1.4e-05	0.000109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUNB—lung cancer	1.39e-05	0.000108	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—TERT—lung cancer	1.35e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—POMC—lung cancer	1.35e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CDKN1A—lung cancer	1.35e-05	0.000105	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PTEN—lung cancer	1.35e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CDKN1A—lung cancer	1.34e-05	0.000105	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PTEN—lung cancer	1.34e-05	0.000104	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EP300—lung cancer	1.34e-05	0.000104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—BRAF—lung cancer	1.33e-05	0.000104	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6R—lung cancer	1.32e-05	0.000102	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CREBBP—lung cancer	1.31e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—FGFR1—lung cancer	1.31e-05	0.000102	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—SRC—lung cancer	1.3e-05	0.000101	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HIF1A—lung cancer	1.29e-05	0.000101	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EP300—lung cancer	1.28e-05	9.95e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STK11—lung cancer	1.26e-05	9.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PLBD1—lung cancer	1.26e-05	9.8e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAP2K1—lung cancer	1.25e-05	9.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—NRAS—lung cancer	1.25e-05	9.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—SRC—lung cancer	1.25e-05	9.72e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOA1—lung cancer	1.25e-05	9.71e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CD—lung cancer	1.25e-05	9.7e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—SRC—lung cancer	1.24e-05	9.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—lung cancer	1.23e-05	9.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGF—lung cancer	1.22e-05	9.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FOXO3—lung cancer	1.22e-05	9.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—NRAS—lung cancer	1.2e-05	9.35e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—STAT3—lung cancer	1.2e-05	9.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—MAPK3—lung cancer	1.2e-05	9.32e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NRAS—lung cancer	1.19e-05	9.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HSD17B10—lung cancer	1.15e-05	8.96e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CASP8—lung cancer	1.15e-05	8.94e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAPK3—lung cancer	1.14e-05	8.92e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6R—lung cancer	1.14e-05	8.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CREBBP—lung cancer	1.14e-05	8.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AVP—lung cancer	1.14e-05	8.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—lung cancer	1.14e-05	8.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—lung cancer	1.14e-05	8.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APC—lung cancer	1.14e-05	8.86e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDH1—lung cancer	1.13e-05	8.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGF—lung cancer	1.12e-05	8.76e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MDM2—lung cancer	1.12e-05	8.69e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MYC—lung cancer	1.11e-05	8.67e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAF1—lung cancer	1.11e-05	8.66e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ERBB2—lung cancer	1.1e-05	8.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IGF1R—lung cancer	1.1e-05	8.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—lung cancer	1.09e-05	8.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAP2K1—lung cancer	1.09e-05	8.49e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—lung cancer	1.09e-05	8.48e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CB—lung cancer	1.09e-05	8.46e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MTOR—lung cancer	1.09e-05	8.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CD—lung cancer	1.08e-05	8.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HES1—lung cancer	1.08e-05	8.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KRAS—lung cancer	1.08e-05	8.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—BRAF—lung cancer	1.07e-05	8.33e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CKB—lung cancer	1.07e-05	8.33e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6R—lung cancer	1.06e-05	8.23e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CREBBP—lung cancer	1.05e-05	8.22e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL8—lung cancer	1.04e-05	8.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KRAS—lung cancer	1.03e-05	8.05e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KRAS—lung cancer	1.03e-05	8.01e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAP2K1—lung cancer	1.01e-05	7.84e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CNDP2—lung cancer	1.01e-05	7.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM2—lung cancer	1.01e-05	7.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CD—lung cancer	1e-05	7.79e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CASP3—lung cancer	9.98e-06	7.78e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—lung cancer	9.97e-06	7.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—PIK3CA—lung cancer	9.88e-06	7.7e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB3—lung cancer	9.87e-06	7.69e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—MTMR3—lung cancer	9.78e-06	7.62e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCND1—lung cancer	9.72e-06	7.57e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MDM2—lung cancer	9.7e-06	7.56e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—JUN—lung cancer	9.7e-06	7.55e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAF1—lung cancer	9.67e-06	7.53e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ERBB2—lung cancer	9.57e-06	7.45e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PGAM1—lung cancer	9.53e-06	7.42e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—PIK3CA—lung cancer	9.49e-06	7.39e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TERT—lung cancer	9.46e-06	7.37e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PIK3CA—lung cancer	9.45e-06	7.36e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CB—lung cancer	9.44e-06	7.36e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MMP9—lung cancer	9.43e-06	7.35e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—lung cancer	9.42e-06	7.34e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CDKN1A—lung cancer	9.4e-06	7.32e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PTEN—lung cancer	9.38e-06	7.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—FGFR1—lung cancer	9.18e-06	7.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HRAS—lung cancer	9.14e-06	7.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2A7—lung cancer	9.09e-06	7.08e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HIF1A—lung cancer	9.04e-06	7.04e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MDM2—lung cancer	8.96e-06	6.98e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EP300—lung cancer	8.94e-06	6.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAF1—lung cancer	8.93e-06	6.96e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDC4—lung cancer	8.9e-06	6.93e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—ERBB2—lung cancer	8.83e-06	6.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HRAS—lung cancer	8.78e-06	6.84e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—lung cancer	8.75e-06	6.82e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—HRAS—lung cancer	8.74e-06	6.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APOA1—lung cancer	8.73e-06	6.8e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CB—lung cancer	8.72e-06	6.79e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—lung cancer	8.7e-06	6.78e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—SRC—lung cancer	8.7e-06	6.78e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—lung cancer	8.67e-06	6.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KDR—lung cancer	8.65e-06	6.74e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTGS2—lung cancer	8.64e-06	6.73e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—VEGFA—lung cancer	8.47e-06	6.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—JUN—lung cancer	8.43e-06	6.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—STAT3—lung cancer	8.39e-06	6.53e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—NRAS—lung cancer	8.37e-06	6.52e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—lung cancer	8.37e-06	6.52e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CDKN1A—lung cancer	8.18e-06	6.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PTEN—lung cancer	8.16e-06	6.36e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—RRM1—lung cancer	8.1e-06	6.31e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA3—lung cancer	8.1e-06	6.31e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—lung cancer	8.07e-06	6.29e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAPK3—lung cancer	8.01e-06	6.24e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—APC—lung cancer	7.97e-06	6.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CG—lung cancer	7.97e-06	6.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—lung cancer	7.97e-06	6.21e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGF—lung cancer	7.87e-06	6.13e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MYC—lung cancer	7.79e-06	6.07e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EP300—lung cancer	7.78e-06	6.06e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—lung cancer	7.75e-06	6.04e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—lung cancer	7.72e-06	6.01e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—lung cancer	7.62e-06	5.94e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—B4GALT5—lung cancer	7.62e-06	5.94e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—POMC—lung cancer	7.58e-06	5.91e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—SRC—lung cancer	7.57e-06	5.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CDKN1A—lung cancer	7.55e-06	5.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PTEN—lung cancer	7.53e-06	5.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—BRAF—lung cancer	7.49e-06	5.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA4—lung cancer	7.41e-06	5.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6R—lung cancer	7.4e-06	5.76e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CREBBP—lung cancer	7.39e-06	5.75e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—STAT3—lung cancer	7.3e-06	5.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—NRAS—lung cancer	7.28e-06	5.67e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA2—lung cancer	7.22e-06	5.63e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KRAS—lung cancer	7.2e-06	5.61e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EP300—lung cancer	7.18e-06	5.6e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAP2K1—lung cancer	7.05e-06	5.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CD—lung cancer	7e-06	5.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—SRC—lung cancer	6.99e-06	5.44e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MAPK3—lung cancer	6.97e-06	5.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTA1—lung cancer	6.97e-06	5.43e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCC3—lung cancer	6.89e-06	5.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—STAT3—lung cancer	6.74e-06	5.25e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NRAS—lung cancer	6.72e-06	5.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKR1C1—lung cancer	6.67e-06	5.2e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—lung cancer	6.63e-06	5.17e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PIK3CA—lung cancer	6.62e-06	5.15e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—UGT1A1—lung cancer	6.48e-06	5.05e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAPK3—lung cancer	6.44e-06	5.01e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—lung cancer	6.4e-06	4.99e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MDM2—lung cancer	6.27e-06	4.89e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KRAS—lung cancer	6.26e-06	4.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MYC—lung cancer	6.26e-06	4.88e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAF1—lung cancer	6.25e-06	4.87e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GNG11—lung cancer	6.25e-06	4.87e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ERBB2—lung cancer	6.19e-06	4.82e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—lung cancer	6.12e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—HRAS—lung cancer	6.12e-06	4.77e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CB—lung cancer	6.1e-06	4.76e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALDOA—lung cancer	5.95e-06	4.63e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL8—lung cancer	5.87e-06	4.57e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—lung cancer	5.86e-06	4.56e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KRAS—lung cancer	5.78e-06	4.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NCOA3—lung cancer	5.77e-06	4.5e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—PIK3CA—lung cancer	5.76e-06	4.48e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ADCY1—lung cancer	5.62e-06	4.38e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCG2—lung cancer	5.62e-06	4.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CASP3—lung cancer	5.61e-06	4.37e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—lung cancer	5.61e-06	4.37e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO2—lung cancer	5.51e-06	4.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—HPGDS—lung cancer	5.51e-06	4.29e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PPP2R1B—lung cancer	5.47e-06	4.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCND1—lung cancer	5.46e-06	4.26e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—JUN—lung cancer	5.45e-06	4.25e-05	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—lung cancer	5.41e-06	4.21e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTT1—lung cancer	5.34e-06	4.16e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HRAS—lung cancer	5.32e-06	4.15e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PIK3CA—lung cancer	5.31e-06	4.14e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MMP9—lung cancer	5.31e-06	4.13e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CDKN1A—lung cancer	5.29e-06	4.12e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2A6—lung cancer	5.28e-06	4.11e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GCLC—lung cancer	5.28e-06	4.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PTEN—lung cancer	5.27e-06	4.11e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—lung cancer	5.1e-06	3.97e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EP300—lung cancer	5.03e-06	3.92e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ENO1—lung cancer	5.01e-06	3.9e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—HRAS—lung cancer	4.92e-06	3.83e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—SRC—lung cancer	4.89e-06	3.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—VEGFA—lung cancer	4.76e-06	3.71e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—STAT3—lung cancer	4.72e-06	3.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—NRAS—lung cancer	4.71e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—lung cancer	4.71e-06	3.67e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—lung cancer	4.7e-06	3.66e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAPK3—lung cancer	4.51e-06	3.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP2E1—lung cancer	4.49e-06	3.5e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—NQO1—lung cancer	4.44e-06	3.46e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MYC—lung cancer	4.38e-06	3.41e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—lung cancer	4.34e-06	3.38e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—lung cancer	4.29e-06	3.34e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KRAS—lung cancer	4.05e-06	3.16e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—STK11—lung cancer	4e-06	3.12e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PIK3CA—lung cancer	3.72e-06	2.9e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTP1—lung cancer	3.7e-06	2.89e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CAT—lung cancer	3.6e-06	2.81e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—lung cancer	3.6e-06	2.8e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ABCB1—lung cancer	3.51e-06	2.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TYMS—lung cancer	3.44e-06	2.68e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—HRAS—lung cancer	3.44e-06	2.68e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GSTM1—lung cancer	3.4e-06	2.65e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—lung cancer	3.3e-06	2.57e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CYP1A1—lung cancer	3.23e-06	2.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ERCC2—lung cancer	3.2e-06	2.49e-05	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—lung cancer	3.04e-06	2.37e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—APOA1—lung cancer	2.77e-06	2.16e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CG—lung cancer	2.53e-06	1.97e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—POMC—lung cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CREBBP—lung cancer	2.34e-06	1.83e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CD—lung cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—lung cancer	2.19e-06	1.71e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CB—lung cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTGS2—lung cancer	1.92e-06	1.49e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PTEN—lung cancer	1.67e-06	1.3e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—EP300—lung cancer	1.6e-06	1.24e-05	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—PIK3CA—lung cancer	1.18e-06	9.2e-06	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—lung cancer	9.64e-07	7.51e-06	CbGpPWpGaD
